Classification and management of refractory coeliac disease

Gut

Volumn 59, Issue 4, 2010, Pages 547-557

  Rubio Tapia, Alberto ^a   Murray, Joseph A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BUDESONIDE; CLADRIBINE; CYCLOSPORIN; INFLIXIMAB; PENTOSTATIN; PREDNISONE; RECOMBINANT INTERLEUKIN 10;

ALGORITHM; CELIAC DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; ENTERITIS; GLUTEN FREE DIET; HUMAN; INTESTINE VILLUS ATROPHY; MALABSORPTION; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REFRACTORY CELIAC DISEASE; RELAPSE; REVIEW; SYMPTOM; T CELL LYMPHOMA; ULCERATIVE JEJUNITIS;

CELIAC DISEASE; DIAGNOSIS, DIFFERENTIAL; DIET, GLUTEN-FREE; HUMANS; IMMUNOPHENOTYPING; INTESTINAL MUCOSA; PROGNOSIS; T-LYMPHOCYTE SUBSETS; TREATMENT FAILURE;

EID: 77950827586     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.195131     Document Type: Review

References (88)

1. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009;373:1480-1493
2. Catassi C. The world map of celiac disease. Acta Gastroenterol Latinoam 2005;35:37-55.
3. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009;137:88-93.
4. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007;26:1217-1225 (Pubitemid 47620425)
5. Green PH, Cellier C. Celiac disease. N Engl J Med 2007;357:1731-1743
6. Murray JA, Watson T, Clearman B, et al. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr 2004;79:669-673 (Pubitemid 41103913)
7. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1981-2002.
8. Daum S, Cellier C, Mulder CJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005;19:413-424
9. Trier JS, Falchuk ZM, Carey MC, et al. Celiac sprue and refractory sprue. Gastroenterology 1978;75:307-316
10. Abdulkarim AS, Burgart LJ, See J, et al. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 2002;97:2016-2021
11. Leffler DA, Dennis M, Hyett B, et al. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007;5:445-450 (Pubitemid 46575362)
12. Biagi F, Corazza GR. Defining gluten refractory enteropathy. Eur J Gastroenterol Hepatol 2001;13:561-565
13. Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007;56:1373-1378 (Pubitemid 47517830)
14. Daum S, Ipczynski R, Schumann M, et al. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 2009;21:66-70.
15. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009;136:81-90.
16. Maurino E, Niveloni S, Chernavsky AC, et al. Clinical characteristics and long-term outcome of patients with refractory sprue diagnosed at a single institution. Acta Gastroenterol Latinoam 2006;36:10-22. (Pubitemid 43529344)
17. Rubio-Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009;136:99-107; quiz 352-353
18. Brar P, Lee S, Lewis S, et al. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol 2007;102:2265-2269 (Pubitemid 47493833)
19. West J. Celiac disease and its complications: a time traveller's perspective. Gastroenterology 2009;136:32-34
20. Al-toma A, Verbeek WH, Mulder CJ. The management of complicated celiac disease. Dig Dis 2007;25:230-236
21. Pietzak MM. Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 2005;128:S135-41.
22. Biagi F, Campanella J, Martucci S, et al. A milligram of gluten a day keeps the mucosal recovery away: a case report. Nutr Rev 2004;62:360-363 (Pubitemid 39299138)
23. Midhagen G, Aberg AK, Olcen P, et al. Antibody levels in adult patients with coeliac disease during gluten-free diet: a rapid initial decrease of clinical importance. J Intern Med 2004;256:519-524 (Pubitemid 39577586)
24. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response. Amino Acids 2007;33:385-394
25. Clemente MG, Musu MP, Frau F, et al. Antitissue transglutaminase antibodies outside celiac disease. J Pediatr Gastroenterol Nutr 2002;34:31-34 (Pubitemid 34251698)
26. Culliford A, Daly J, Diamond B, et al. The value of wireless capsule endoscopy in patients with complicated celiac disease. Gastrointest Endosc 2005;62:55-61. (Pubitemid 40922441)
27. Daum S, Wahnschaffe U, Glasenapp R, et al. Capsule endoscopy in refractory celiac disease. Endoscopy 2007;39:455-458 (Pubitemid 46785085)
28. Baer AN, Bayless TM, Yardley JH. Intestinal ulceration and malabsorption syndromes. Gastroenterology 1980;79:754-765
29. Hadithi M, Al-toma A, Oudejans J, et al. The value of doubleballoon enteroscopy in patients with refractory celiac disease. Am J Gastroenterol 2007;102:987-996 (Pubitemid 46698230)
30. Huppert BJ, Farrell MA, Kawashima A, et al. Diagnosis of cavitating mesenteric lymph node syndrome in celiac disease using MRI. AJR Am J Roentgenol 2004;183:1375-1377 (Pubitemid 44210604)
31. Mallant M, Hadithi M, Al-Toma AB, et al. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol 2007;13:1696-1700 (Pubitemid 46711340)
32. Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006;47:1622-1627 (Pubitemid 47545027)
33. Nath SK. Tropical sprue. Curr Gastroenterol Rep 2005;7:343-349
34. Owens SR, Greenson JK. The pathology of malabsorption: current concepts. Histopathology 2007;50:64-82.
35. Akram S, Murray JA, Pardi DS, et al. Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin Gastroenterol Hepatol 2007;5:1282-90; quiz 1245.
36. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol 2008;103:190-195
37. Rubio-Tapia A, Van Dyke CT, Lahr BD, et al. Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol Hepatol 2008;6:983-987
38. Rashtak S, Murray JA. Tailored testing for celiac disease. Ann Intern Med 2007;147:339-341
39. Zone JJ. Skin manifestations of celiac disease. Gastroenterology 2005;128:S87-91.
40. Lewis NR, Scott BB. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). Aliment Pharmacol Ther 2006;24:47-54.
41. When is a coeliac a coeliac? Report of a working group of the United European gastroenterology week in Amsterdam, 2001. Eur J Gastroenterol Hepatol 2001;13:1123-1128
42. Rubio-Tapia A, Murray JA. Novel endoscopic methods for the evaluation of the small-bowel mucosa. Gastrointest Endosc 2007;66:382-386 (Pubitemid 47069304)
43. Campanella J, Biagi F, Ilaria Bianchi P, et al. Clinical response to gluten withdrawal is not an indicator of coeliac disease. Scand J Gastroenterol 2008:1-4.
44. Westergaard H. Tropical sprue. Curr Treat Options Gastroenterol 2004;7:7-11.
45. Fine KD, Meyer RL, Lee EL. The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. Gastroenterology 1997;112:1830-1838
46. See J, Murray JA. Gluten-free diet: the medical and nutrition management of celiac disease. Nutr Clin Pract 2006;21:1-15. (Pubitemid 43190701)
47. Kaukinen K, Peraaho M, Lindfors K, et al. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007;25:1237-1245
48. Rubio-Tapia A, Barton SH, Rosenblatt JE, et al. Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. J Clin Gastroenterol 2009;43:157-161
49. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000;18:795-803.
50. Meresse B, Ripoche J, Heyman M, et al. Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis. Mucosal Immunol 2009;2:8-23.
51. Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007;132:1902-1911
52. Verbeek WH, Van De Water JM, Al-Toma A, et al. Incidence of enteropathy - associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol 2008:1-7.
53. Verbeek WH, von Blomberg BM, Scholten PE, et al. The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease. Am J Gastroenterol 2008;103:3152-3158
54. Swinson CM, Slavin G, Coles EC, et al. Coeliac disease and malignancy. Lancet 1983;1:111-115
55. Ryan BM, Kelleher D. Refractory celiac disease. Gastroenterology 2000;119:243-251
56. Potter DD, Murray JA, Donohue JH, et al. The role of defective mismatch repair in small bowel adenocarcinoma in celiac disease. Cancer Res 2004;64:7073-7077
57. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000;356:203-208
58. Patey-Mariaud De Serre N, Cellier C, Jabri B, et al. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology 2000;37:70-77
59. Verbeek WH, Goerres MS, von Blomberg BM, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008;126:48-56.
60. Cellier C, Patey N, Mauvieux L, et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998;114:471-481
61. Tjon JM, Verbeek WH, Kooy-Winkelaar YM, et al. Defective synthesis or association of T-cell receptor chains underlies loss of surface T-cell receptor-CD3 expression in enteropathy-associated T-cell lymphoma. Blood 2008;112:5103-5110
62. Ashton-Key M, Diss TC, Pan L, et al. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol 1997;151:493-498 (Pubitemid 27330068)
63. de Mascarel A, Belleannee G, Stanislas S, et al. Mucosal intraepithelial T-lymphocytes in refractory celiac disease: a neoplastic population with a variable CD8 phenotype. Am J Surg Pathol 2008;32:744-751 (Pubitemid 351600824)
64. Liu H, Brais R, Lavergne-Slove A, et al. Continual monitoring of intraepithelial lymphocyte immunophenotype and clonality is more important than snapshot analysis in the surveillance of refractory coeliac disease. Gut 2009 [Epub ahead of print].
65. Verkarre V, Romana SP, Cellier C, et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 2003;125:40-46 (Pubitemid 36799105)
66. Verbeek WH, von Blomberg BM, Coupe VM, et al. Aberrant T-lymphocytes in refractory coeliac disease are not strictly confined to a small intestinal intraepithelial localization. Cytometry B Clin Cytom 2009;76:367-374
67. Daum S, Hummel M, Weiss D, et al. Refractory sprue syndrome with clonal intraepithelial lymphocytes evolving into overt enteropathy-type intestinal T-cell lymphoma. Digestion 2000;62:60-65 (Pubitemid 30481291)
68. Cellier C, Cerf-Bensussan N. Treatment of clonal refractory celiac disease or cryptic intraepithelial lymphoma: A long road from bench to bedside. Clin Gastroenterol Hepatol 2006;4:1320-1321 (Pubitemid 44716756)
69. Haines ML, Anderson RP, Gibson PR. Systematic review: The evidence base for long-term management of coeliac disease. Aliment Pharmacol Ther 2008;28:1042-1066
70. Olaussen RW, Lovik A, Tollefsen S, et al. Effect of elemental diet on mucosal immunopathology and clinical symptoms in type 1 refractory celiac disease. Clin Gastroenterol Hepatol 2005;3:875-885 (Pubitemid 41219290)
71. Goerres MS, Meijer JW, Wahab PJ, et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther 2003;18:487-494
72. Daum S, Ipczynski R, Heine B, et al. Therapy with budesonide in patients with refractory sprue. Digestion 2006;73:60-68 (Pubitemid 43800663)
73. Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology 2009;136:2092-2100
74. Bonderup OK, Hansen JB, Teglbjaerg PS, et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 2009;58:68-72.
75. Wahab PJ, Crusius JB, Meijer JW, et al. Cyclosporin in the treatment of adults with refractory coeliac disease-an open pilot study. Aliment Pharmacol Ther 2000;14:767-774
76. Maurino E, Niveloni S, Chernavsky A, et al. Azathioprine in refractory sprue: results from a prospective, open-label study. Am J Gastroenterol 2002;97:2595-2602
77. Gillett HR, Arnott ID, McIntyre M, et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002;122:800-805 (Pubitemid 34173833)
78. Longstreth GF. Successful treatment of refractory sprue with cyclosporine. Ann Intern Med 1993;119:1014-1016 (Pubitemid 23334658)
79. Vivas S, Ruiz de Morales JM, Ramos F, et al. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006;354:2514-2515 (Pubitemid 43855075)
80. Verbeek WH, Mulder CJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med 2006;355:1396-7; author reply 1397.
81. Mulder CJ, Wahab PJ, Meijer JW, et al. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol 2001;13:1183-1188 (Pubitemid 33015884)
82. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004;2:731-743 (Pubitemid 39200711)
83. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-1252 (Pubitemid 24158045)
84. Al-Toma A, Goerres MS, Meijer JW, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006;4:1322-7; quiz 1300.
85. Dray X, Joly F, Lavergne-Slove A, et al. A severe but reversible refractory sprue. Gut 2006;55:1210-1211
86. Al-toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007;109:2243-2249 (Pubitemid 46348229)
87. Al-Toma A, Verbeek WH, Visser OJ, et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis 2007;39:634-641 (Pubitemid 46888208)
88. Mention JJ, Ben Ahmed M, Begue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003;125:730-745 (Pubitemid 37070691)